In a report published Monday, Jefferies analyst Biren Amin initiated coverage on Bellicum Pharmaceuticals BLCM with a Buy rating and $35.00 price target.
In the report, Jefferies noted, “BLCM appears poised to be a leading player in the development of suicide safety switches for T-cell engineered products w/ its lead program, BPX-501, in ongoing PI/II focused on resolution of acute GVHD in patients undergoing stem cell transplant. BLMC has developed a suicide switch platform which it employs across its pipeline to potentially influence efficacy/safety. We initiate with a Buy and $35 PT.”
Bellicum Pharmaceuticals closed on Friday at $31.75.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in